Bismuth subsalicylate (Bismol) for Diarrhea

Bismuth subsalicylate (Bismol) has got antisecretory, anti-inflammatory, and anti-diarrheal properties. It is used to treat the following conditions:

  • For the symptomatic treatment of diarrhea.

  • For the treatment of indigestion, relief of gas, heartburn, upset stomach, and nausea.

  • As a part of combination therapy for the eradication of H.pylori infection.

  • For the treatment and prophylaxis of travelers diarrhea.

Bismuth subsalicylate Dose in Adults

Dose in the treatment of Dyspepsia and Diarrhea:

  • 524 mg orally every half to one hour or 1,050 mg every one hour as needed for up to 2 days
  • The maximum dose should not exceed 4,200 mg per day [8 doses (regular strength); 4 doses (maximum strength)]

Dose in the prophylaxis of Traveler's diarrhea ( off-label use):

  • 524 mg orally four times a day with meals and at bedtime.
  • Safety beyond 3 weeks has not been established.

Dose in the treatment of Traveler's diarrhea (as off-label use):

  • 524 mg orally every half to one hour as needed up to 8 doses/24 hours

Off label use as a part of a combination regimen for the eradication of Helicobacter pylori infection:

  • Bismuth quadruple therapy:
    • 300 mg orally four times a day (in combination with tetracycline 500 mg four times a day, either metronidazole 500 mg 3 or 4 times a day, and standard-dose proton pump inhibitor two times a day) for 10 - 14 days.

Bismuth subsalicylate Dose in Childrens

Note: Patients allergic to aspirin should avoid bismuth subsalicylate. Furthermore, it should not be used during a viral illness such as chickenpox or flu due to the risk of Reye syndrome.


Dose in the treatment of Diarrhea:

  • Children 3 - 12 years:
    • Regular strength:
      • 3 - 6 years:
        • 87 mg orally every half to one hour as needed.
      • 6 - 9 years:
        • 175 mg orally every half to one hour as needed.
      • 9 - 12 years:
        • 262 mg orally every half to one hour as needed
      • Note: Do not exceed 8 doses/day
  • Children older than 12 years and Adolescents:
    • Regular strength:
      • 524 mg orally every half to one hour as needed.
    • Maximum strength:
      • 1,050 mg orally every hour as needed
    • The total dose  should not exceed 8 doses per day (regular strength) or four doses per day (maximum strength)

Dose in the treatment of Dyspepsia:

  • Children older than 12 years and Adolescents:
    • Regular strength:
      • 524 mg orally every half to one hour as needed.
    • Maximum strength:
      • 1,050 mg orally every hour as needed
    • The total dose  should not exceed 8 doses per day (regular strength) or four doses per day (maximum strength)

Dose in the treatment of chronic Diarrhea:

  • Infants older than 2 months:
    • 44 mg orally every 4 -  6 hours
  • Children less than 2 years:
    • 44 mg orally every 4 hours or 87 mg four times a day.
  • Children 2 to 3 years of age:
    • 87 mg orally every 4 - 6 hours
  • Children 3 to 4 years of age:
    • 87 mg orally every four hours
  • Children 4 - 6 years:
    • 175 mg orally every four hours

Bismuth Subcalicylate dose in the treatment of Helicobacter pylori-associated antral gastritis (as part of combination therapy):

  • Children and Adolescents:
    • 8 mg/kg/day orally in two divided doses for 10 - 14 days.
    • The dose may be administered four times a day.

Pregnancy Risk Factor: C

  • The drug's salicylates component crosses the placental boundary.
  • It should not be used for acute diarrhea during pregnancy.
  • It is also not recommended for the prevention or treatment of traveler's diarrhea.

Use of bismuth subsalicylates during breastfeeding

  • Breastmilk is a source of the drug's salicylate component. Case reports have reported adverse reactions.
  • Avoid it while breastfeeding.
  • It is not recommended to treat or prevent traveler's diarrhoea while breastfeeding

Bismuth subsalicylate Dose in Renal Disease:

  • Adjustment in the dose has not been recommended in patients with renal disease.

Bismuth subsalicylate Dose in Liver Disease:

  •  Adjustment in the dose has not been recommended in patients with liver disease.

Side Effects Frequency not defined

  • Central Nervous System:
    • Anxiety
    • Confusion
    • Depression
    • Headache
    • Slurred Speech
  • Gastrointestinal:
    • Grayish black fecal Discoloration
    • Tongue Discoloration
  • Neuromuscular & Skeletal:
    • Muscle Spasm
    • Weakness
  • Otic:
    • Hearing Loss
    • Tinnitus

Contraindication to Bismuth subsalicylate include:

  • Patients allergic to salicylates or those who take other salicylates should not use it.
  • Patients suffering from peptic ulcer disease
  • Melena and black tarry stool are signs of gastrointestinal bleeding.

Warnings and Precautions

  • Neurotoxicity:
    • Neurotoxic effects may occur if you take large amounts. Patients with neurological diseases should be cautious.

Bismuth subsalicylate: Drug Interaction

Risk Factor C (Monitor therapy)

Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.)

May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.

Ajmaline

Salicylates may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased.

Ammonium Chloride

May increase the serum concentration of Salicylates.

Angiotensin-Converting Enzyme Inhibitors

Salicylates may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors.

Anticoagulants

Salicylates may enhance the anticoagulant effect of Anticoagulants.

Benzbromarone

Salicylates may diminish the therapeutic effect of Benzbromarone.

Blood Glucose Lowering Agents

Salicylates may enhance the hypoglycemic effect of Blood Glucose Lowering Agents.

Corticosteroids (Systemic)

Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.

Loop Diuretics

Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.

Potassium Phosphate

May increase the serum concentration of Salicylates.

Probenecid

Salicylates may diminish the therapeutic effect of Probenecid.

Salicylates

May enhance the anticoagulant effect of other Salicylates.

Thrombolytic Agents

Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.

Valproate Products

Salicylates may increase the serum concentration of Valproate Products.

Risk Factor D (Consider therapy modification)

Carbonic Anhydrase Inhibitors

Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination. Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated. If another combination is used, monitor patients closely for adverse effects. Tachypnea, anorexia, lethargy, and coma have been reported. Exceptions: Brinzolamide; Dorzolamide.

Ginkgo Biloba

May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.

Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry)

May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.

Hyaluronidase

Salicylates may diminish the therapeutic effect of Hyaluronidase. Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.

Methotrexate

Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.

Nonsteroidal Anti-Inflammatory Agents (Nonselective)

May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal AntiInflammatory Agents (Nonselective).

PRALAtrexate

Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.

Tetracyclines

Bismuth Subsalicylate may decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable. Exceptions: Eravacycline.

Varicella Virus-Containing Vaccines

Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.

Vitamin K Antagonists (eg, warfarin)

Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.

Risk Factor X (Avoid combination)

Bismuth Subcitrate

Bismuth-Containing Compounds may enhance the neurotoxic effect of Bismuth Subcitrate.

Dexketoprofen

Salicylates may enhance the adverse/toxic effect of Dexketoprofen. Dexketoprofen may diminish the therapeutic effect of Salicylates. Salicylates may decrease the serum concentration of Dexketoprofen. Management: The use of high-dose salicylates (3 g/dayor more in adults) together with dexketoprofen is inadvisable. Consider administering dexketoprofen 30-120 min after or at least 8 hrs before cardioprotective doses of aspirin to minimize any possible interaction.

Influenza Virus Vaccine (Live/Attenuated)

May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.

Sulfinpyrazone

Salicylates may decrease the serum concentration of Sulfinpyrazone.

How to take Bismuth subsalicylate?

  • The oral formulation should be shaken well before its use.
  • The chewable tablets should be chewed thoroughly and allowed to dissolve in the mouth before swallowing.
  • The non-chewable tablets should be swallowed with a full glass of water. 

Mechanism of action of Bismuth subsalicylate:

  • It is antimicrobial, antisecretory and has some anti-inflammatory properties.
  • Bismuth is antimicrobial and can be used to fight both bacterial pathogens and viruses. 
  • The salicylate component has antisecretory properties.

Bismuth is less than 1%absorbedHowever, over 80% of subsalicylate components are absorbed. More than 90% is absorbed.

Proteins bound. It isMetabolizedIn the gastrointestinal tract, and converted into bismuth or salicylic acid in there.

The terminalHalf-life eliminationThe time it takes to make bismuth from bismuth is between 21 and 72 days, while the time it takes to make salicylate is between 2 and 5 hours.

The urine excretes the salicylate, while the urine excretes the bismuth.

International Brands of Bismuth subsalicylate:

  • Bismatrol Maximum Strength
  • Bismatrol
  • Diotame
  • Geri-Pectate
  • Kao-Tin
  • Peptic Relief
  • Pepto-Bismol InstaCool
  • Pepto-Bismol
  • Pink Bismuth
  • Stomach Relief Max St
  • Stomach Relief
  • Bisbacter
  • Bismucar
  • Bismutol
  • Bitni X Forte Suspension
  • Facidmol
  • Gastro-Bismol
  • Gastro-Bismol L
  • Kalbeten
  • Peptolite
  • Pink Bismuth
  • Stobiol

Bismuth subsalicylate brands in Pakistan:

Bismuth Subsalicylates [Susp 88 mg/5ml]

Akso-D Akson Pharmaceuticals (Pvt) Ltd.
Bismol Macter International (Pvt) Ltd.

Bismuth Subsalicylates [Tabs 265 mg]

Akso-D Akson Pharmaceuticals (Pvt) Ltd.
Bismol Macter International (Pvt) Ltd.

Comments

NO Comments Found